Use of cookies
Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)
Direct Healthcare Professional Communication (DHPC) on combined hormonal contraceptives: Prescribing those with the lowest risk of venous thromboembolism and use of the officially mandated education material material.
2021.09.30
Active substance: combined hormonal contraceptives
The Federal Institute for Drugs and Medical Devices (BfArM) would like to inform you once again, that combined hormonal contraceptives (CHCs) with the progestogens levonorgestrel, norethisterone or norgestimate have the lowest risk of venous thromboembolism (VTE). Whenever a CHC is prescribed, the different VTE risks of the individual CHCs should be taken into account and those with the lowest VTE risk in particular should be prescribed.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN